{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T02:55:20Z","timestamp":1790996120168,"version":"4.1.0"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:00:00Z","timestamp":1790985600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T00:00:00Z","timestamp":1790985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur Arch Otorhinolaryngol"],"DOI":"10.1007\/s00405-026-10647-5","type":"journal-article","created":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T02:26:09Z","timestamp":1790994369000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-world two-year outcomes of mepolizumab in patients with chronic rhinosinusitis with nasal polyps and coexisting severe asthma"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0297-2711","authenticated-orcid":false,"given":"Juan","family":"Riestra-Ayora","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1013-1650","authenticated-orcid":false,"given":"Carlos","family":"Fern\u00e1ndez-Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9627-525X","authenticated-orcid":false,"given":"Cristina","family":"Vaduva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1911-2419","authenticated-orcid":false,"given":"Beatriz Rodr\u00edguez","family":"Jim\u00e9nez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5337-837X","authenticated-orcid":false,"given":"Lorena Mart\u00edn","family":"Zaragoza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1175-3844","authenticated-orcid":false,"given":"Eduardo","family":"Mart\u00edn-Sanz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zully V\u00e1squez","family":"Gambasica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,3]]},"reference":[{"key":"10647_CR1","doi-asserted-by":"publisher","unstructured":"Latorre M et al (Jan. 2020) Upper and lower airway inflammation in severe asthmatics: a guide for a precision biologic treatment. Ther Adv Respir Dis 14:1753466620965151. https:\/\/doi.org\/10.1177\/1753466620965151","DOI":"10.1177\/1753466620965151"},{"issue":"6","key":"10647_CR2","doi-asserted-by":"publisher","first-page":"976","DOI":"10.3390\/jpm12060976","volume":"12","author":"A Bakakos","year":"2022","unstructured":"Bakakos A, Schleich F, Bakakos P (2022) Biological therapy of severe asthma and nasal polyps. J Pers Med 12(6):976. https:\/\/doi.org\/10.3390\/jpm12060976","journal-title":"J Pers Med"},{"issue":"0","key":"10647_CR3","doi-asserted-by":"publisher","first-page":"0","DOI":"10.4193\/Rhin23.415","volume":"0","author":"WJ Fokkens","year":"2024","unstructured":"Fokkens WJ et al (2024) EPOS2020\/EUFOREA expert opinion on defining disease states and therapeutic goals in CRSwNP. Rhinology J 0(0):0\u20130. https:\/\/doi.org\/10.4193\/Rhin23.415","journal-title":"Rhinology J"},{"issue":"2","key":"10647_CR4","doi-asserted-by":"publisher","first-page":"82","DOI":"10.4193\/Rhin20.601","volume":"58","author":"WJ Fokkens","year":"2020","unstructured":"Fokkens WJ et al (2020) Executive summary of EPOS 2020 including integrated care pathways. Rhinology J 58(2):82\u2013111. https:\/\/doi.org\/10.4193\/Rhin20.601","journal-title":"Rhinology J"},{"issue":"1","key":"10647_CR5","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1164\/rccm.200801-060ST","volume":"180","author":"HK Reddel","year":"2009","unstructured":"Reddel HK et al (2009) An official american thoracic society\/European respiratory society statement:Asthma control and exacerbations. Am J Respir Crit Care Med 180(1):59\u201399. https:\/\/doi.org\/10.1164\/rccm.200801-060ST","journal-title":"Am J Respir Crit Care Med"},{"key":"10647_CR6","doi-asserted-by":"publisher","unstructured":"Detoraki A et al (Jan. 2021) Mepolizumab improves sino-nasal symptoms and asthma control in severe eosinophilic asthma patients with chronic rhinosinusitis and nasal polyps: a 12-month real-life study. Ther Adv Respir Dis 15:17534666211009398. https:\/\/doi.org\/10.1177\/17534666211009398","DOI":"10.1177\/17534666211009398"},{"issue":"10","key":"10647_CR7","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1111\/all.13496","volume":"73","author":"ACA Yii","year":"2018","unstructured":"Yii ACA, Tay T-R, Choo XN, Koh MSY, Tee AKH, \u2010Y D, Wang (2018) Precision medicine in united airways disease: A \u2018treatable traits\u2019 approach. Allergy 73(10):1964\u20131978. https:\/\/doi.org\/10.1111\/all.13496","journal-title":"Allergy"},{"issue":"3","key":"10647_CR8","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1007\/s11136-004-1597-x","volume":"14","author":"I Alobid","year":"2005","unstructured":"Alobid I, Ben\u00edtez P, Bernal-Sprekelsen M, Guilemany JM, Picado C, Mullol J (2005) The impact of asthma and aspirin sensitivity on quality of life of patients with nasal polyposis. Qual Life Res 14(3):789\u2013793. https:\/\/doi.org\/10.1007\/s11136-004-1597-x","journal-title":"Qual Life Res"},{"key":"10647_CR9","unstructured":"Alobid I, Bernal-Sprekelsen M, Mullol J (2021) and Gu\u00eda de pr\u00e1ctica cl\u00ednica para el diagn\u00f3stico y tratamiento de la poliposis nasal (POLINA). Acta Otorrinolaringol Esp, 72( 2)"},{"issue":"12","key":"10647_CR10","doi-asserted-by":"publisher","first-page":"2312","DOI":"10.1111\/all.13875","volume":"74","author":"WJ Fokkens","year":"2019","unstructured":"Fokkens WJ et al (2019) EUFOREA consensus on biologics for CRSwNP with or without asthma, Allergy 74(12):2312\u20132319. https:\/\/doi.org\/10.1111\/all.13875","journal-title":"Allergy"},{"issue":"0","key":"10647_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4193\/Rhin20.600","volume":"0","author":"WJ Fokkens","year":"2020","unstructured":"Fokkens WJ et al (2020) European position paper on rhinosinusitis and nasal polyps 2020. Rhinology J 0(0):1\u2013464. https:\/\/doi.org\/10.4193\/Rhin20.600","journal-title":"Rhinology J"},{"issue":"9","key":"10647_CR12","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1111\/all.16618","volume":"80","author":"F Schleich","year":"2025","unstructured":"Schleich F et al (2025) Mepolizumab effectiveness in severe asthma with\/without chronic rhinosinusitis with nasal polyps: Real-world pooled analysis. Allergy 80(9):2557\u20132571. https:\/\/doi.org\/10.1111\/all.16618","journal-title":"Allergy"},{"issue":"2","key":"10647_CR13","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1007\/s00405-024-08903-7","volume":"282","author":"H Wang","year":"2025","unstructured":"Wang H et al (2025) Efficacy of different biologics for treating chronic rhinosinusitis with nasal polyps: a network meta-analysis. Eur Arch Otorhinolaryngol 282(2):559\u2013569. https:\/\/doi.org\/10.1007\/s00405-024-08903-7","journal-title":"Eur Arch Otorhinolaryngol"},{"issue":"155","key":"10647_CR14","doi-asserted-by":"publisher","first-page":"190151","DOI":"10.1183\/16000617.0151-2019","volume":"29","author":"D Price","year":"2020","unstructured":"Price D, Castro M, Bourdin A, Fucile S, Altman P (2020) Short-course systemic corticosteroids in asthma: striking the balance between efficacy and safety. Eur Respir Rev 29(155):190151. https:\/\/doi.org\/10.1183\/16000617.0151-2019","journal-title":"Eur Respir Rev"},{"issue":"1","key":"10647_CR15","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1186\/s12890-025-03911-7","volume":"25","author":"A Tsukada","year":"2025","unstructured":"Tsukada A (2025) Comparative efficacy of biologics for uncontrolled asthma patients with chronic rhinosinusitis or nasal polyps: a systematic review and network meta-analysis. BMC Pulm Med 25(1):432. https:\/\/doi.org\/10.1186\/s12890-025-03911-7","journal-title":"BMC Pulm Med"},{"issue":"10","key":"10647_CR16","doi-asserted-by":"publisher","first-page":"2684","DOI":"10.1111\/all.15796","volume":"78","author":"RJL van der Lans","year":"2023","unstructured":"van der Lans RJL et al (2023) Two-year results of tapered dupilumab for CRSwNP demonstrates enduring efficacy established in the first 6 months. Allergy 78(10):2684\u20132697. https:\/\/doi.org\/10.1111\/all.15796","journal-title":"Allergy"},{"issue":"9","key":"10647_CR17","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.3390\/jpm14091014","volume":"14","author":"E De Corso","year":"2024","unstructured":"De Corso E (2024) Sinonasal outcomes obtained after 2 years of treatment with benralizumab in patients with severe eosinophilic asthma and CRSwNP: A \u2018real-life\u2019 observational study. J Pers Med 14(9):1014. https:\/\/doi.org\/10.3390\/jpm14091014","journal-title":"J Pers Med"},{"issue":"3","key":"10647_CR18","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.jaci.2020.05.032","volume":"146","author":"P Gevaert","year":"2020","unstructured":"Gevaert P (2020) Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials. J Allergy Clin Immunol 146(3):595\u2013605. https:\/\/doi.org\/10.1016\/j.jaci.2020.05.032","journal-title":"J Allergy Clin Immunol"}],"container-title":["European Archives of Oto-Rhino-Laryngology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00405-026-10647-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00405-026-10647-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00405-026-10647-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T02:26:11Z","timestamp":1790994371000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00405-026-10647-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,3]]},"references-count":18,"alternative-id":["10647"],"URL":"https:\/\/doi.org\/10.1007\/s00405-026-10647-5","relation":{},"ISSN":["0937-4477","1434-4726"],"issn-type":[{"value":"0937-4477","type":"print"},{"value":"1434-4726","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,3]]},"assertion":[{"value":"26 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"J. Riestra has received advisory board fees and speaker honoraria from GlaxoSmithKline (GSK) and Sanofi. C. Vaduva has received speaker honoraria from GlaxoSmithKline (GSK) and Sanofi. These activities were unrelated to the present study. The remaining authors declare no conflicts of interest.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Artificial intelligence-assisted tools were used only for language editing. All scientific content and final revisions were performed and approved by the authors.","order":2,"name":"Ethics","label":"Artificial intelligence statement","group":{"name":"EthicsHeading","label":"Declarations"}}]}}